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Abstract 
Background:  
Children hospitalised with severe anaemia in malaria endemic areas in Africa are at high risk of 
readmission or death within 6 months post-discharge. Currently, no strategy specifically addresses this 
period. In Malawi, 3 months of post-discharge malaria chemoprevention (PMC) with monthly treatment 
courses of artemether-lumefantrine given at discharge and at 1 and 2 months prevented 30% of all-
cause readmissions by 6 months post-discharge. Another efficacy trial is needed before a policy of 
malaria chemoprevention can be considered for the post-discharge management of severe anaemia in 
children under 5 years of age living in malaria endemic areas. 
Objective 
We aim to determine if 3 months of post-discharge malaria chemoprevention with monthly 3-day 
treatment courses of dihydroartemisinin-piperaquine is safe and superior to a single 3-day treatment 
course with artemether-lumefantrine provided as part of standard in-hospital care in reducing all-cause 
re-admissions and deaths (composite primary endpoint) by 6 months in the post-discharge management 
of children less than 5 years of age admitted with severe anaemia of any or undetermined cause. 
Methods 
This is a multi-centre, 2-arm, placebo-controlled, individually randomized trial in children under 5 years 
of age recently discharged following management for severe anaemia. Children in both arms will receive 
standard in-hospital care for severe anaemia and a 3-day course of artemether-lumefantrine at 
discharge. At 2 weeks after discharge surviving children will be randomized to receive either 3-day 
courses of dihydroartemisinin-piperaquine at 2, 6 and 10 weeks or an identical placebo and followed for 
26 weeks through passive case detection. The trial will be conducted in hospitals in malaria endemic 
areas in Kenya and Uganda. The study is designed to detect a 25% reduction in the incidence of the all-
cause re-admissions or death (composite primary outcome) from 1,152 to 864 per 1000 child years 
(power 80%, α=0.05) and requires 520 children per arm (1040 total children).  
Results 
Participant recruitment started in May 2016 and is on-going. 
Trial registration:  
ClinicalTrials.gov NCT02671175, Registered January 28, 2016. 
https://clinicaltrials.gov/ct2/show/NCT02671175  
Keywords: Malaria, severe anaemia, chemoprevention, post-discharge, readmission, mortality, 
dihydroartemisinin-piperaquine, protocol, cost-effectiveness 
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Background 
Severe anaemia, defined as haemoglobin (Hb) concentration level below 5.0 g/dL or haematocrit below 
15.0%  [1], is a major public health problem in low and middle-income countries. Severe anaemia is 
associated with approximately one third of hospital admissions among febrile children in sub-Saharan   
Africa contributing substantially to paediatric morbidity and mortality especially in malaria endemic 
areas [2, 3]. Children under 5 years of age are most vulnerable to the long term effects of severe 
anaemia including decreased cognitive performance, mental and motor development[4]. Rates of in-
hospital mortality due to severe anaemia ranging from 4 to 12% have been reported in different 
epidemiological settings [5-7]. In addition, these reports indicate a high post-discharge mortality and 
morbidity, especially in the first 3 to 6 months. Longitudinal follow-up of children aged less than 5 years 
admitted with severe anaemia in Malawi showed that 8.2% died by 6 months post-discharge and 5.9% 
were readmitted with severe anaemia, compared to those without severe anaemia among whom 1.6% 
died and 0.5% were readmitted [8, 9]. Similar high rates of post-discharge mortality (10% by 8 weeks) 
were observed in malaria endemic areas of western Kenya [10] and in Uganda, where 12% died or were 
readmitted within 6 months [11]. 
Standard in-hospital treatment of severe anaemia in many countries in sub-Saharan Africa consists of a 
blood transfusion and parenteral artesunate for severe malaria[12]. In the case of severe malarial 
anaemia, this is completed with a 3-day course of artemisinin-based combination therapy (ACT), usually 
artemether-lumefantrine. Children are often discharged with a short course of iron and folate, typically 
with no further scheduled follow-up. Haematological recovery from malaria-associated anaemia takes at 
least 6 weeks [13, 14]. However, many children in these areas experience episodes of new or 
recrudescent malaria infections after discharge which negates the initial rise in haemoglobin achieved 
by blood transfusion resulting in delayed haematological recovery and potentially rebound of severe 
anaemia and death in some [10, 15-17]. Furthermore, delayed haemolytic anaemia occurring 1 to 3 
weeks after artesunate treatment of falciparum malaria has been reported in non-immune traveller [18, 
19], although more recent studies show this to be rare in African children [20]. 
Malaria control strategies in endemic and epidemic prone areas includes Intermittent Preventive 
Therapy (IPT). IPT is the administration of a full treatment course using long-acting antimalarials at pre-
defined time intervals irrespective of a patient’s malaria status to clear existing infections and to provide 
prolonged prophylaxis against new infections [21]. The World Health Organisation (WHO) recommends 
IPT as a malaria control strategy in malaria endemic areas for pregnant women (IPTp)[22, 23], infants 
(IPTi) [24] and for children in areas with seasonal malaria transmission (‘seasonal malaria 
chemoprevention’, or SMC)[25]. Currently, no control strategy specifically addresses the high-risk post-
discharge period for children previously treated for severe anaemia in malaria endemic areas. In Malawi, 
3 months of malaria chemoprevention with 3 full treatment courses of artemether-lumefantrine, given 
in-hospital to children under 5 years of age admitted with severe malaria anaemia, and at 1 and 2 
months post-discharge, prevented 31% of deaths or readmissions by 6 months post-discharge, and 30% 
of all-cause readmissions [17]. These results are consistent with earlier findings from The Gambia which 
showed that in children with severe anaemia, chemoprevention targeted during the malaria 
transmission season halved the rate of clinical malaria and reduced all-cause hospital readmission by 
78% in one trial, and recurrence of severe anaemia by 78% in the other [26, 27]. These data indicate that 
malaria chemoprevention in the post-discharge period may provide substantial health benefits. 
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We are conducting an efficacy trial in Kenya and Uganda to determine the efficacy and safety of 3 
months of malaria chemoprevention post-discharge as a potentially cost-effective strategy to reduce all-
cause readmissions and deaths in children admitted with severe anaemia. We hypothesize that by 
creating a prophylactic-time-window post-transfusion for malaria, more time is assured for bone-
marrow recovery, resulting in a more sustained haematological recovery post-discharge.  
We refer to this strategy as post-discharge malaria chemoprevention, PMC, to illustrate the similarities 
with SMC rather than with IPT in pregnancy as it aims to provide complete, rather than intermittent 
prophylaxis. 
Study Design and Methods  
Design overview 
This will be a multi-centre, parallel group, two-arm, placebo-controlled, individually randomized, 
superiority trial with 1:1 allocation ratio comparing the safety and efficacy of three courses of monthly 
PMC-DP or placebo post-discharge provided in addition to the standard single 3-day treatment course 
with artemether lumefantrine given as part of routine in-hospital care (ClinicalTrials.gov: NCT02671175. 
Registered January 28, 2016). Randomisation to PMC with DP or placebo will occur at 2 weeks after 
enrolment, and PMC treatments will be administered at 2, 6 and 10 weeks. The primary outcome will be 
the number of all-cause deaths or all-cause re-admissions between 2-26 weeks after enrolment 
(composite outcome). The study will be conducted in Uganda and Kenya, using randomisation stratified 
by weight and study centre. The study will include a total of 1040 children (520 per study arm) less than 
5 years of age who have been admitted for severe anaemia and have successfully completed the 
standard in-hospital treatment. 
Primary objective 
The primary objective is to determine if 3 months of post discharge malaria chemoprevention with 
monthly 3-day treatment courses of DP is superior to the single 3-day treatment course with 
artemether-lumefantrine provided as part of standard in-hospital care in reducing all-cause 
readmissions and deaths by 6 months in the post-discharge management of children less than 5 years of 
age admitted with severe anaemia.  
Secondary objectives 
The secondary objectives include the determination of the safety of 3 courses of monthly DP and the 
cost-effectiveness of PMC-DP compared to current standard of care. 
Design Considerations 
Rationale for choice of DP for PMC 
Optimal antimalarial prophylaxis with maximum compliance would be provided by a regimen that is long 
acting so that administration is not required more frequently than monthly. Sulphadoxine, mefloquine, 
and DP have sufficiently long half-lives to be considered [28]. However, there is high-level resistance to 
sulphadoxine in many parts of east and southern Africa, precluding its use for this purpose in these 
malaria endemic areas[29]. Both amodiaquine [30] and mefloquine are poorly tolerated; which is an 
important consideration when providing drugs for malaria prevention to recipients with few or no 
symptoms [31, 32]. DP is very effective, well tolerated, and provides 4 to 5 weeks of post-treatment 
prophylaxis, and is therefore currently the drug of choice for use for evaluation as part of IPT and 
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malaria chemoprevention in areas with high-grade parasite resistance to sulphadoxine [33-38]. 
Furthermore, recent studies show that artemether-lumefantrine and DP exert inverse selective pressure 
on P. falciparum drug sensitivity [39], suggesting that the use of DP may be a good choice for 
chemoprevention in areas where artemether-lumefantrine is the first-line drug of choice for case-
management.  
Why in this study population? 
The primary study population involves children with severe anaemia, rather than only children with 
severe malarial anaemia, which was the study population in the previous trial in Malawi [17]. This is 
based on observational studies in Malawi, Uganda and western Kenya showing that children admitted 
with severe anaemia appear to be at increased risk of readmission and death regardless of whether they 
had evidence of malaria infection at the time of admission or not [Desai et al, unpublished observations; 
Richard Opoko, unpublished observations] [17]. Second, reliable diagnosis of presence of malaria is 
difficult and the differentiation between severe anaemia and severe malaria anaemia is not always 
feasible as it is common practice in many hospitals in sub-Saharan Africa to start parenteral treatment 
with antimalarials before the laboratory diagnosis of malaria is available. Furthermore, the 
interpretation of malaria diagnostic tests on admission may be complicated in children who received 
antimalarial treatment just prior to admission [40]. 
Efficacy and effectiveness of delivery mechanisms 
This current trial is an efficacy trial and each treatment course will be provided by study staff directly. 
The first dose of each course will be observed, and where feasible, doses on day 2 and 3 will also be 
given under supervision, or compliance verified by home visits or contacting caretakers by mobile 
phone. A separate trial, focusing on effectiveness of different delivery mechanisms is being conducted 
by our consortium members in Malawi (NCT02721420). 
Why this composite primary outcome? 
Use of clinical malaria as primary outcome would require a smaller study, however the composite 
outcome is used because it is more likely to drive policy. We use a composite outcome rather than a 
single severe outcome, such as death, to keep sample size requirements manageable. 
Rationale for assessment by 6 months after enrolment 
The period 2-26 weeks, instead of 0-26 weeks is used for the primary efficacy analysis because children 
will not be randomized until 2 weeks after enrolment. Prior to 2 weeks, all children, including those in 
the placebo arm, will receive a 3-day course of artemether-lumefantrine as part of standard in-hospital 
care, which will be started before discharge and completed at home after discharge. The duration of 
post-treatment prophylaxis in our previous trial with artemether-lumefantrine is about 2 to 3 weeks [17] 
and we therefore do not anticipate any differential effect between the arms until children receive their 
first study specific intervention upon randomisation. The protective drug levels have waned in many 
children by 14 weeks (i.e. about 4 weeks after the last PMC course of DP), but we follow the children for 
a total of 26 weeks to capture any potential prolonged benefits or rebound effects.  
Study settings 
The study will be conducted in hospitals in Kenya and Uganda located in areas with moderate to intense 
malaria transmission [41, 42]. The annual entomological inoculation rates vary widely, in Western Kenya 
from 31.1 to 108.6 infective bites/person/year [43, 44]in areas around Kisumu and Siaya respectively, 
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while in Uganda from 2.8 to 4 infective bites/person/year [45, 46] in areas around Jinja and Mubende 
respectively. In western Kenya, we will recruit participants from hospitals located in areas around Lake 
Victoria with well documented malaria transmission intensity, including the Jaramogi Oginga Odinga 
teaching and referral hospital, Siaya, Kisumu, Homa Bay and Migori County referral hospitals. In Uganda, 
we will recruit from Jinja, Hoima, Masaka and Mubende regional referral hospitals as well as Kamuli 
mission hospital (Figure 1)  
Inclusion and exclusion criteria  
The inclusion and exclusion criteria for pre-study screening, enrolment and for randomisation 2 weeks 
later are shown below. 
Eligibility criteria 
Eligibility criteria for pre-study screening 
INCLUSION CRITERIA FOR ENROLMENT INTO PRE-STUDY SCREENING PERIOD 
1. Haemoglobin <5.0 g/dl or parked cell volume < 15%, or requirement for blood transfusion for 
other clinical reasons on or during admission to the hospital 
2. Aged less than 59.5 months 
3. Body weight ≥5 kg 
4. Resident in catchment area 
EXCLUSION CRITERIA FOR ENROLMENT INTO PRE-STUDY SCREENING PERIOD 
1. Recognised specific other cause of severe anaemia e.g. trauma, haematological malignancy, 
known bleeding disorder 
2. Known sickle cell disease 
3. Child will reside for more than 25% of the 6 months study period (i.e. 6 weeks or more) outside 
of catchment area 
Eligibility criteria for enrolment into study 
INCLUSION CRITERIA FOR ENROLMENT: 
1. Fulfilled the pre-study screening eligibility criteria 
2. Aged less than 59.5 months 
3. Clinically stable, able to take oral medication  
4. Subject completed blood transfusion(s) or became clinically stable without transfusion 
5. Able to feed (for breastfeeding children) or eat (for older children) 
6. Provision of informed consent by parent or guardian 
EXCLUSION CRITERIA FOR ENROLMENT: 
1. Previous enrolment in the present study 
2. Known hypersensitivity to study drug  
3. Use or known need at the time of enrolment for concomitant prohibited medication including 
drugs known to prolong the QTc interval during the 14 weeks PMC treatment period (Additional 
file 1), section 8.5.7, page 34) 
4. Ongoing or planned participation in another clinical trial involving ongoing or scheduled 
treatment with prohibited medicinal products or active follow-up during the study 
5. A known need for scheduled surgery during the subsequent course of the study 
6. Anticipated non-compliance with the follow-up schedule 
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7. Know heart conditions, or family history of congenital prolongation of the QTc interval 
Eligibility criteria for randomisation into study (at 2 weeks post-discharge) 
INCLUSION CRITERIA FOR RANDOMISATION:  
1. Fulfilled enrolment eligibility criteria and was enrolled during recent admission 
2. Aged <60 months 
3. Still clinically stable, able to take oral medication, able to feed (for breastfeeding children) or eat 
(for older children) and able to sit unaided (for older children who were already able to do so 
prior to hospitalisation) 
EXCLUSION CRITERIA FOR RANDOMISATION: 
1. Used DP since enrolment 
2. Use or known need at the time of randomisation for concomitant prohibited medication 
(Additional file 1) section 8.5.7, page 34). 
3. Enrolled, or known agreement to enrol into another clinical trial involving ongoing or scheduled 
treatment with medicinal products during the study. 
4. Withdrawal of consent since enrolment 
Interventions 
Trial Medication and Interventions 
Children will be randomized to one of the two treatment groups: DP or placebo. Children in both arms 
will receive standard in-hospital care and, at discharge (enrolment) a 3-day course of artemether 
lumefantrine regardless of whether they were admitted with severe malarial anaemia or severe 
anaemia without evidence of malaria. 
ARTEMETHER-LUMEFANTRINE  
The study will use a Good Manufacturing Practice (GMP) formulation of artemether-lumefantrine 
(Coartem®, Novartis Pharmaceuticals). The recommended treatment is a 6-dose regimen over a 3-day 
period with dosing per bodyweight following WHO dosing recommendations as provided for in the 
latest WHO malaria treatment guidelines [12] (see Additional file 1, Table 3, page 29).  
DIHYDROARTEMISININ-PIPERAQUINE 
The study will use the Eurartesim® brand of DP from Alfasigma (formerly Sigma Tau), Italy, a co-
formulated tablet containing 40 mg dihydroartemisinin and 320 mg piperaquine phosphate or as 20/160 
(paediatric formulation). Dosing will be per bodyweight according to the schedule recommended by 
current WHO’s Guidelines (Additional file 1), Table 4, page 30). 
PLACEBO DP 
Placebos for DP will be manufactured by Alfasigma, Italy. The dosage regimen for DP-placebo will be 
identical in number of tablets per day and timing of the dose to that of the active DP product. The drug 
administration procedures will also be identical to that for the active drugs.  
Other medication 
STANDARD IN-HOSPITAL AND POST-DISCHARGE CARE 
Except for the full 3-day course of artemether-lumefantrine all care provided prior to and following 
enrolment of the participants in the study (at convalescence) will be according to local (hospital) or 
national guidelines, and therefore not subject to this study. Treatment for malaria in both Kenya and 
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Uganda conforms with the current WHO malaria treatment guidelines [12], which includes artemether-
lumefantrine as first line treatment for uncomplicated malaria and parenteral artesunate for severe 
malaria. Details of non-study specific care provided by the hospital staff will be recorded.  
IRON AND FOLATE SUPPLEMENTATION 
All children will receive 28 days iron and folate supplementation at 2 weeks post discharge as part of 
routine care for severe anaemia. A standardized prophylactic dose of iron supplementation (about 2 
mg/kg) will be given as mono-therapy or as part of the fixed-dose formulation with folic acid (Additional 
file 1, section 0, page 7 for details about iron supplementation).  
Outcomes 
The Primary and secondary efficacy outcomes are shown below: 
Primary efficacy outcome 
The number of all-cause deaths or all-cause re-admissions between 2-26 weeks after enrolment 
(composite outcome).  
Key secondary efficacy outcomes 
1. Readmission due to severe malaria (defined as any treatment with parenteral quinine or 
artesunate, or presence of severe anaemia and treatment with oral antimalarials) by 26 weeks 
from randomisation 
2. Readmissions due to severe anaemia (defined as Hb <5g/dL or Packed Cell Volume <15% or 
requirement for blood transfusion based on other clinical indication) by 26 weeks from 
randomisation 
3. Readmission due to severe malarial anaemia (severe anaemia plus parenteral or oral 
antimalarial treatment) by 26 weeks from randomisation 
4. Readmission due to severe anaemia or severe malaria (composite outcome) by 26 weeks from 
randomisation 
5. All-cause mortality by 26 weeks from randomisation 
6. All-cause hospital readmission by 26 weeks from randomisation 
7. Clinic visits because of smear- or malaria rapid diagnostic test (RDT)- confirmed non-severe 
malaria by 26 weeks from randomisation 
Other secondary efficacy outcomes 
1. Readmission due to severe malaria-specific anaemia (severe anaemia plus parenteral or oral 
antimalarial treatment and parasite density >5000/microlitre) by 26 weeks from randomisation 
2. Readmission due to severe disease other than severe anaemia and severe malaria by 26 weeks 
from randomisation 
3. Non-severe all-cause sick-child clinic visits by 26 weeks from randomisation 
4. Non-malaria sick child clinic visits by 26 weeks from randomisation 
5. Malaria infection at 26 weeks 
6. Hb at 26 weeks 
7. Any anaemia (Hb<11 g/dL), mild anaemia (Hb 8.0-10.99 g/dl) moderate anaemia (Hb 5.0-7.99 
g/dL) and severe anaemia (Hb<5 g/dL) at 26 weeks 
8. Weight-for-age, height-for-age, and height-for-weight Z-scores [standard deviation (SD) scores 
of reference population] at 26 weeks 
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Tolerability and safety outcomes 
1. Serious adverse events, excluding primary and secondary efficacy outcomes, by 26 weeks from 
randomisation 
2. Serious adverse events within 7 days after the start of each course of PMC, excluding primary 
and secondary efficacy outcomes 
3. Adverse events by 26 weeks from randomisation 
4. Adverse events within 7 days after start of each course of PMC 
5. QTc prolongation measured by electrocardiogram (ECG) 4-6 hours after 3rd dose of each course 
(in a subset of patients) 
Participants timeline  
Overview of study phases and scheduled visits (Table 1 and additional file 2) 
The study timelines consist of an in-patient pre-study screening period while the patient is acutely ill 
(visit 1), followed by a screening, consent and enrolment visit (visit 2). During the convalescence phase 
in the hospital, patients receive artemether-lumefantrine (visit 3), prior to discharge. The patient returns 
to the study clinic 14 days later (visit 4) for randomisation. Home treatment visits are made at 6 (visit 5) 
and 10 (visit 6) weeks. The PMC period starts at 2 weeks and ends at 14 weeks, but participants are 
followed up for an additional 12 weeks through passive follow-up and then seen at 26 weeks (visit 7) for 
an end of study assessment.  
Unscheduled Visits (passive follow-up) 
A passive surveillance system is in place to monitor intercurrent illnesses during the observation period. 
Parents are instructed to bring their child to the study clinic for any suspected illness. Blood samples for 
Hb, malaria diagnosis (RDT and smear) and filter paper dry blood spot (DBS) for parasite genetics are 
obtained. Verbal autopsy is conducted for children who die at home during the follow up period. 
Adverse events and vital status are assessed during all scheduled or unscheduled visits.  
Sample Size 
Original sample size 
The initial estimate of the required  sample size of 2212 children (1106 per arm) across both countries 
pooled, and was designed to detect a 30% reduction in the incidence rate of the composite primary 
outcome (death or all-cause readmission) from 469 per 1000 child years in the control arm to 328 per 
1000 child years in the intervention arm (power 90%, α=0.05), which allowed for one interim analysis 
and 15.7% loss to follow-up. For these estimations, we assumed an average pooled event rate of 399 
per 1000 child years across the two arms, with 328 and 469 events per 1000 child years in the 
intervention and control arms, respectively (RR=0.70). We  based this assumption on observations in 
western Kenya (Desai et al, unpublished) and Malawi [17]. However, the observed event rate, pooled 
across both arms, during the first year of the study was 1,120/1000 child years, which is almost three 
times higher than the assumed event rates. The higher rate is consistent with the recently published 
observations in Uganda [11]. Furthermore, the observed rate of loss to follow-up in the first 533 
participants recruited and followed up for 6 Months was 7% rather than the assumed 15%.  
Sample size re-estimation 
Following recommendations from the Data Monitoring and Ethics Committee (DMEC) and The Trial 
Steering Committee (TSC), a blinded interim sample size re-estimation was conducted to take into 
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account the lower than expected rate of loss to follow-up and the higher than expected pooled 
incidence rate of the composite primary endpoint (death or all-cause readmission). This was favoured 
over an interim analysis, because the available funding did not allow an extension of the recruitment 
period, even if the results of any interim analysis had suggested that this would be required.  
The revised sample size calculations show that a total sample size of 1040 children (520 per arm) is 
required to detect a 25% reduction in the incidence of the composite primary outcome from 1,152 per 
1000 child years (530 events per 1000 children) in the control arm to 864 per 1000 child years (398 per 
1000 children) in the intervention arm (power 80%, α=0.05), allowing for 10% loss to follow-up. The 
same sample size also provides 90% power to detect a 28.7% reduction in the primary endpoint from 
1,152 to 822 events per 1000 children years. 
Assignment of interventions 
Allocation  
Eligible children are randomly assigned (1:1) to either PMC-DP or placebo by a computer-generated 
randomisation schedule stratified by weight (per DP dosing schedule) and study site using permuted 
blocks of random sizes (see Additional file 1, page 30, Table 4) [12] Recruitment is ‘competitive’ between 
the sites in the trial. 
Blinding  
The study is double-blinded to both participants/caretakers and study staff. Allocation concealment is 
achieved by use of sealed opaque envelopes, with each envelope containing 3 other small envelopes 
(one for each PMC course). The envelopes containing active DP or placebo look identical, and the 
appearance and consistency of the tablets is also identical. 
Laboratory Procedures 
Hb is measured using HemoCue201 (Angelholm, Sweden) photometers. Thick and thin blood films for 
parasite counts is obtained and examined. The films are read by two independent miscroscopists by 
counting any malaria parasites against 200 high power fields before a slide is declared negative[47]. 
Point of care malaria diagnosis will be conducted using First Response® Malaria Ag. pLDH/HRP2 Combo 
Card Test 
Statistical Methods 
A detailed study statistical analytical plan for the final analysis, that will supersede the study protocol, 
will be developed during the study before the unblinding of data. 
Analysis Populations 
The intention-to-treat population (ITT) is defined as all randomized subjects allocated to one of the two 
treatment arms and will be analysed in the group to which they were randomized, regardless of the type 
(placebo or active PMC) or number of courses received. The per-protocol (PP) population is a subset of 
the ITT population; excluding participants with major protocol deviations.   
Missing Data 
Every effort is being made to minimise the amount of missing data in the trial, and whenever possible, 
information on the reason for missing data is obtained. No adjustments will be made for missing 
outcome data, but missing data may be imputed for co-variates.  
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Assessment of efficacy 
Primary analysis will be by intention to treat, and include all primary endpoint events (i.e. first and 
repeat events). The follow-up time will be measured as the time in days from the date of randomisation 
to the end of follow-up (around 26 weeks), death or drop-out. The incidence rate will be calculated per 
arm and the incidence rate ratio (IRR, PMC to placebo) and 95% CI estimated using Poisson regression 
models with treatment (as randomised) as the only co-variate. The results will also be expressed as the 
relative rate reduction (RRR) (95% CI). 
Subgroup analysis 
We will use stratified analysis to assess to what extent the effect of the intervention on the primary 
outcome is influenced by country, demographic parameters (e.g. age, ethnicity and socio-economic 
status), clinical parameters, malaria transmission variables (malaria transmission intensity, residence 
(urban/rural), season, insecticide treated nets use, site), time of assessment and potential intervention 
modifiers. Because we did not power the study for subgroup analyses, we will interpret the results of 
the subgroup analysis cautiously. No adjustment will be made for multiple comparisons.  
Sensitivity analysis 
A number of sensitivity analyses will be conducted to assess the robustness of the primary endpoint 
analysis. These include analysis of the per-protocol subject population, and covariate adjusted analysis. 
Other regression models will also be explored. Additional post-hoc analyses may also be conducted if 
deemed appropriate. In addition, we will compare the results of the covariate-adjusted analyses with 
and without imputation for missing values for co-variates values at baseline.  
Analysis of adverse events 
Adverse events and serious adverse events are monitored, managed, and recorded during the study. 
They will be recorded and tabulated for each treatment arm, overall, and per body system. Treatment 
emergent adverse events are defined as adverse events that had an onset day on or after the day of the 
first dose of study medication. No formal statistical testing will be undertaken.  Enrolled children who 
are clinically unstable 2 weeks post-discharge (i.e. at the time eligibility is assessed for randomization) 
and/or have rebound severe anaemia, are re-admitted and become eligible for randomization if they 
fulfil the entry criteria two weeks after the subsequent discharge. 
Procedures for Assessing Efficacy and safety Parameters 
Primary Efficacy outcome 
ALL-CAUSE MORTALITY  
This will be assessed during visits 4 (2 weeks), 5 (6 weeks), 6 (10 weeks), and 18 weeks (by phone) and 
during end of study assessment at 26 weeks.  
ALL-CAUSE AND DISEASE SPECIFIC RE-ADMISSIONS 
This will be assessed through passive case detection and through a questionnaire administered during 
visits 4-7 at 2, 6, 10, 26 weeks and during unscheduled sick visits. Details of admissions and treatment 
that the participants received are recorded, including malaria diagnostic test results and use of 
antimalarials to allow for differentiation between malaria, severe anaemia, and other syndromes. 
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Secondary Efficacy Outcomes 
ALL-CAUSE AND MALARIA SPECIFIC CLINIC VISITS 
This will be assessed through passive case detection and through questionnaires administered during 
visits 4-7 at 2, 6, 10, 26 weeks and during unscheduled sick visits. Details of clinic visits are recorded 
including malaria diagnosis results to allow for differentiation between malaria and non-malaria clinic 
visits. 
Adverse Events  
We will adhere to the International Conference on Harmonisation (ICH) good clinical practice (GCP) 
principles in recording, reporting and managing adverse events and serious adverse events for all 
participants in both arms (see Additional file 1, page 51, section 9.6.2). 
Cardiac monitoring sub-study 
The main safety concern with DP is its dose-dependent QTc prolongation induced by the piperaquine 
component. Transient QTc prolongation has been confirmed in clinical trials but there are no data 
suggesting that the treatment is associated with clinically significant arrhythmias [38, 48, 49]. A trial in 
Uganda among children 6 to 24 months old included monthly DP for up to 18 monthly courses. A 
detailed sub-study of the effect of DP on cardiac repolarization was conducted in 26 children and 
concluded that DP is not associated with a trend toward increasing QTc prolongation with increasing 
number of DP courses [38]. This type of safety data is limited and we will therefore conduct a nested 
cardiac monitoring sub-study at Jinja Regional Referral Hospital in Uganda among 66 children who will 
be selected through convenience sampling. Separate written informed consent will be sought for 
inclusion in this sub-study. Approximately half of these children are expected to have received PMC with 
DP. The primary objective is to determine whether transient QTc prolongation increases in magnitude 
with subsequent courses of DP. Children enrolled into the sub-study will have an ECG taken prior to the 
first dose of each course and again 4-6 hours after taking the 3rd dose of each course of DP (anticipated 
maximum drug concentration).  
Discussions 
Severe anaemia and severe malaria is a major public health problem in malaria endemic areas of Africa.  
Evidence suggests that a major, potentially preventable, component of the burden occurs after 
discharge and that a proactive approach is needed. Currently, no strategy specifically addresses this 
high-risk post-discharge period. This study seeks to determine the efficacy, safety and cost-effectiveness 
of 3 months of malaria chemoprevention post-discharge as an innovative strategy to reduce all-cause 
readmissions and deaths among children admitted with severe anaemia in malaria endemic areas. The 
study settings in Kenya and Uganda are representative of the main epidemiological settings appropriate 
for this intervention. Members from our consortium, under the leadership of the College of Medicine in 
Malawi, are concurrently conducting a trial in Malawi, under a separate protocol, on potential delivery 
mechanisms and health services research to determine the uptake, effectiveness, acceptability and 
feasibility of different mechanisms for delivering PMC (clinicaltrials.gov: NCT02721420). This strategy 
builds on existing approaches used for seasonal malaria chemo-prevention in west Africa and experience 
with IPT in pregnant women and infants [50, 51]. Should PMC prove to be effective, cost-effective and 
feasible, PMC may be a promising strategy to reduce all-cause readmissions and deaths in children 
admitted with severe anaemia in malaria endemic areas of Africa. 
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Trial status 
Recruitment started in May 2016 and is ongoing. Unblinding and analysis will begin after recruitment 
and follow up is completed, the database has been completed, cleaned, and locked. 
Abbreviations and acronyms 
ACT artemisinin-based combination therapy    
AL artemether-lumefantrine     
CDC Disease Control and Prevention    
CGHR Center for Global Health Research   
CI confidence interval     
DBS dry blood spot     
DP dihydroartemisinin-piperaquine    
DSMB Data Safety and Monitoring Board   
ECG electrocardiogram      
EDCTP European & Developing Countries Clinical Trials Partnership  
GCP good clinical practice     
GLOBVAC Global Health and Vaccination Research    
GMP good manufacturing practice     
Hb haemoglobin     
ICH International Conference on Harmonisation   
IPT intermittent preventive therapy   
IPTi intermittent preventive therapy in infants  
IPTp intermittent preventive therapy in pregnancy  
IPTpd intermittent preventive therapy post-discharge   
ITNs insecticide treated nets    
ITT intention-to-treat      
KEMRI Kenya Medical Research Institute   
LSTM Liverpool School of Tropical Medicine   
PMC post-discharge malaria chemoprevention   
PP per-protocol      
RDT rapid diagnostic test     
RRR relative rate reduction    
SA severe anaemia     
SMA severe malaria anaemia     
SMC seasonal malaria chemoprevention   
SOMREC School of Medicine Research and Ethics Committee  
SP sulphadoxine pyrimethamine     
SSA sub-Saharan Africa      
TSC Trial Steering Committee    
WHO World Health Organisation     
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Figures 
Figure 1: Map of study setting in Kenya and Uganda 
Study sites in both western Kenya and Uganda are in the lake endemic region. These are large referral 
hospitals in the region with adequate diagnostic and treatment capacities for malaria and other 
conditions.
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Tables  
Table 1: Study Design and Schedule of Assessment (Spirit figure) 
Phase Recruitment Phase 
En
ro
lm
en
t 
In-patient Hospitalisation phase 
R
an
d
o
m
is
at
io
n
 
PMC 
Treatment Phase 
12 weeks period from 2-14 weeks 
Post-PMC 
Extended 
follow-up 
Phase 
Location In-Hospital Clinic/
Home 
Home Clinic/home 
Visit number #1 #2 #3 #4 #5 #6 #7 
Visit description 
Pre-study 
Screening 
Screening 
Consent & Base-
line 
AL treatment visit 
t=2 weeks;  
Allocation & 
treatment visit 
t=6 weeks 
treatment visit 
T=10 weeks 
treatment visit 
End of study 
Assessment 
Study Time 
Days -4a-0 Day0 
Day0 
Hosp 
Day1 
hosp/
home 
Day2 
hosp/
home 
2 weeks  
(day 14[11-28])c 
6 weeks  
(day 42 [38-56])c 
10 weeks  
(day 70 [66-84])c 
6 Month 
(day 182 +/- 
28)c 
2w-
Day1 
2w-
Day2 
2w-
Day3 
6w- 
Day1 
6w-
Day2 
6w-
Day3 
10w-
Day1 
10w-
Day2 
10w-
Day3 
Recruitment                
  Pre-screening eligibility X               
  Prior consent discussion X               
Enrolment                
  Eligibility screen  X              
  Informed Consent  X              
  Study code issued  X              
  Allocation      X          
Interventions                
  PMC-Placebo arm   AL1&2b AL3&4b AL5&6b Plac1 Plac2 Plac3 Plac1 Plac2 Plac3 Plac1 Plac2 Plac3  
  PMC-Active arm   AL1&2b AL3&4b AL5&6b DP1 DP2 DP3 DP1 DP2 DP3 DP1 DP2 DP3  
  Iron supplement. 
     
Iron for 28 days from t=14-42 
days 
      
Assessments                
Baseline                
  Copy Clinic/Lab data from hospital records X    X          
  Physical Exam.  X    X          
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  Blood sample 
 2ml VP    
FP-
Hb/M
Se 
         
Efficacy Outcomes                
  Physical exam/growth               X 
  Hb & Malaria & PCR               X 
  Clinic visits 
  
Passive surveillance in clinics in the catchment area, 26 weeks from 0-26 weeks (clinical malaria and other acute 
illnesses) (RDT/smear, Hb, dried blood spots for parasite genetics) 
  Hospitalisation   Passive surveillance for hospital admission in the catchment area, 26 weeks from 0-26 weeks 
  Vital status   X X X X X X X X X X X X X 
  Pf genetics/resistance Xf X    X         X 
  Host genetics  X             X 
  Patient costs     X          X 
Safety Outcomes                
  Adverse events   X X X X X X X X X X X X X 
  ECGd      X  X X  X X  X  
Visit #1: Pre-study Screening (around admission or shortly thereafter) 
Visit #2: Screening Consent & Base-line (during convalescence) 
Visit #3: Oral artemether-lumefantrine (AL) consisting of 6 doses (2x daily for 3 days); first dose provided in hospital. Subsequent doses may be administered at home or in-hospital. 
Visit #4: 2 weeks after enrolment. Participants will be randomised to one of the two treatment groups during this visit. They will also be given the first dose of PMC under observation. 
Doses of day 2 and 3 can be taken at home. All participants will get 1-month supply of iron during this visit. 
Visit #5 #6: Home visits at 6 and 10 weeks after enrolment to issue participants with the 2nd and 3rd course of the PMC study drugs.  
Visit #7: at 6 months after enrolment. This is the close out assessment. 
a. Children can be pre-study screened any time between hospital admission and enrolment. The figure of -4 days is provided for illustration purposes only. 
b. AL: Some children may have received AL as part of standard in-hospital care prior to enrolment (e.g. during days -1 or -2 and not as part of the study). They will have their number 
of study AL doses adjusted to ensure that no more than a cumulative total of 6 AL doses is provided. The day of enrolment is always considered as Day-0 regardless of when the 
first dose of AL was received. 
c.  Visit window= number of days an actual subject visit may fall outside of the planned protocol schedule visit to still meet protocol requirements. DP should be given at least 4 
weeks apart.  
d. ECG, Electro Cardio Gram, to be conducted in a sub-sample only. A capillary sample will be taken at the same time as the ECG for piperaquine drug levels. 
e. MS, malaria smear. This will be collected for research purposes only and read days to weeks later. Malaria smears will not be used for point of care. If participants are symptomatic 
(e.g. fever) an RDT will be taken for point of care. 
f. Uses left over samples from blood-group typing and cross-matching or other clinical samples that were taken as part of routine care that would otherwise be discarded. Sample 
will only be used after consent has been obtained in the subsequent visit 2. 
VP=vena puncture. FP=finger prick, Plac=Placebo DP, DP=dihydroartemisinin-piperaquine, AL=artemether-lumefantrine, Hb=haemoglobin, MS=malaria smear, Pf=Plasmodium 
falciparum 
 
